Issues
-
Cover Image
Cover Image
Human prostate cancer selectively metastasizes to the bone with mechanisms that are partially unknown. RAGE is a receptor overexpressed by prostate cancer cells whose expression correlates with the capacity of colonizing the bone marrow microenvironment. Proteinase 3 (PR3) is a serine protease produced and released by myeloid cells, and has been identified as a RAGE-interacting protein. Using high resolution confocal microscopy, it was found that soluble PR3 (red) accumulates at the surface of prostate cancer cells overexpressing RAGE (green). This result supports further evidence of heterotypic cell-cell interactions between prostate cancer cells expressing RAGE and hematopoietic cells expressing PR3. For more details, see article by Kolonin and colleagues on page 3144. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Advances
Reviews
Perspective
Priority Reports
Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone
Molecular and Cellular Pathobiology
Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis
TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis
tRF/miR-1280 Suppresses Stem Cell–like Cells and Metastasis in Colorectal Cancer
Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion
Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation
Tumor and Stem Cell Biology
p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis
IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition
Therapeutics, Targets, and Chemical Biology
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
Microenvironment and Immunology
Integrated Systems and Technologies
An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma
Letter to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.